OOIR: Observatory of International Research

Papers

(The TQCC of Blood Reviews is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Interplay between platelets and coagulation	173
Targeting MCL-1 in hematologic malignancies: Rationale and progress	137
Coagulation and anticoagulation in COVID-19	135
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system	123
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes	109
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	102
Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents	93
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	74
The looming storm: Blood and cytokines in COVID-19	66
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved	66
Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment	65
A review of FLT3 inhibitors in acute myeloid leukemia	64
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities	57
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map	55
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research	51
Role of inflammation in the biology of myeloproliferative neoplasms	50
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions	50
Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation	48
Current state and next-generation CAR-T cells in multiple myeloma	46
Illness and prognostic understanding in patients with hematologic malignancies	46
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities	42
Inherited thrombocytopenias: an updated guide for clinicians	41
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies	40
Current management strategies for polycythemia vera and essential thrombocythemia	40
Discussing investigational AAV gene therapy with hemophilia patients: A guide	39

Current and emerging strategies for management of myelodysplastic syndromes	37
Second primary malignancies in multiple myeloma: A review	34
Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer	34
IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly	31
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature	30
Complement activation in COVID-19 and targeted therapeutic options: A scoping review	30
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation	29
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies	28
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options	27
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models	26
Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians	26
It takes two to thrombosis: Hemolysis and complement	25
CLL update 2022: A continuing evolution in care	25
Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management	25
Optimising prophylaxis in haemophilia A: The ups and downs of treatment	25
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness	25
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic	24
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?	24
Immune thrombocytopenia: A review of upfront treatment strategies	24
The critical roles of iron during the journey from fetus to adolescent: Developmental aspects of iron homeostasis	23
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag	23
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways	23
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?	23
Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation	22
l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?	22
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	22
Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions	21
Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations	21
Metabolic regulation of the bone marrow microenvironment in leukemia	21
Hormonal replacement therapy in adolescents and young women with chemo- or radio-induced premature ovarian insufficiency: Practical recommendations	21
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option	21
Artificial intelligence in hematological diagnostics: Game changer or gadget?	20
Management of challenging myelofibrosis after JAK inhibitor failure and/or progression	20
Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment	20
Magnesium: The overlooked electrolyte in blood cancers?	19
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	19
A review on how to do hematology consults during COVID-19 pandemic	19
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity	19
Revisiting Richter transformation in the era of novel CLL agents	18
Peripheral neuropathy in hematologic malignancies – Past, present and future	18
AML and the art of remission maintenance	18
Germline genetic factors in the pathogenesis of myeloproliferative neoplasms	17
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	17
The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia	17
The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation	17
Diagnosis of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics	17
A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia	17
Determinants of severity in sickle cell disease	17
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia	17
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap	17

Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned	16
Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization	16
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management	16
Health related quality of life in children with sickle cell disease: A systematic review and meta-analysis	16
Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review	16
Advances in the management of TTP	16